The George Institute For Global Health
Global
United Kingdom
India
China
Australia

Publications

Found 8133 results
2019
Singh G, Sharma S, Bansal R, et al. A home-based, primary-care model for epilepsy care in India: Basis and design. Epilepsia Open. 2019. doi:10.1002/epi4.12311.
Nambiar D, Mishra A. ‘A light inside a pot’: Sites and sources of power emerging from an ethnography of traditional healing in South India. Global Public Health. 2019. doi:10.1080/17441692.2018.1564349.
McCaughey T, Budden D, Sanfilippo P, et al. A Need for Better Understanding Is the Major Determinant for Public Perceptions of Human Gene Editing. Hum Gene Ther. 2019;30:36 - 43. doi:10.1089/hum.2018.033.
McCaughey T, Budden D, Sanfilippo P, et al. A Need for Better Understanding Is the Major Determinant for Public Perceptions of Human Gene Editing. Human Gene Therapy. 2019;30:36 - 43. doi:10.1089/hum.2018.033.
Lipman J, Brett S, De W, et al. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc. 2019;21:63 - 68. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30857514.
Gálvez O, Glue P, Somogyi A, et al. A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology. 2019;33:260 - 261. doi:10.1177/0269881118822147.
Liu Z, Li Q, Maddison R, et al. A School-Based Comprehensive Intervention for Childhood Obesity in China: A Cluster Randomized Controlled Trial. Childhood Obesity. 2019;15:105 - 115. doi:10.1089/chi.2018.0251.
Macniven R, Hunter K, Lincoln M, et al. Accessibility of Primary, Specialist, and Allied Health Services for Aboriginal People Living in Rural and Remote Communities: Protocol for a Mixed-Methods Study. JMIR Res Protoc. 2019;8:e11471. doi:10.2196/11471.
Ohkuma T, Jun M, Rodgers A, et al. Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension (Dallas, Tex. : 1979). 2019;73:84 - 91. doi:10.1161/HYPERTENSIONAHA.118.12060.
Iseki K, Kenealy T, Klein B, et al. Adiposity and risk of decline in glomerular filtration rate: Meta-analysis of individual participant data in a global consortium. BMJ (Online). 2019;364. doi:10.1136/bmj.k5301.
Wilson J, Blizzard L, Gall S, et al. An age- and sex-specific dietary guidelines index is a valid measure of diet quality in an Australian cohort during youth and adulthood. Nutrition Research. 2019;65:43 - 53. doi:10.1016/j.nutres.2019.01.007.
Robinson T, Bray B, Paley L, et al. Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Progra. International Journal of Stroke. 2019. doi:10.1177/1747493019841246.
Fretts A, Imamura F, Marklund M, et al. Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. The American journal of clinical nutrition. 2019;109:1216 - 1223. doi:10.1093/ajcn/nqz005.
Heerspink H, Parving H, Andress D, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. The Lancet. 2019;393:1937 - 1947. doi:10.1016/S0140-6736(19)30772-X.
Lioufas N, Toussaint N, Pedagogos E, et al. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) st. BMJ open. 2019;9:e024382. doi:10.1136/bmjopen-2018-024382.
Zhou Z, Lindley R, Rådholm K, et al. Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 2019;50:396 - 404. doi:10.1161/STROKEAHA.118.023009.
Coresh J, Heerspink H, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. The Lancet Diabetes and Endocrinology. 2019;7:115 - 127. doi:10.1016/S2213-8587(18)30313-9.
Heerspink H, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. The Lancet Diabetes and Endocrinology. 2019;7:128 - 139. doi:10.1016/S2213-8587(18)30314-0.
Harrison T, Tam-Tham H, Hemmelgarn B, et al. Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular an